Evidence map›Paper›PMID 35818801›Full record

ReviewExpert opinion on biological therapy2022

Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?

Gunay Uludag, Muhammad Hassan, Wataru Matsumiya, Brandon Huy Pham, Sophaktra Chea, Ngoc Trong Tuong Than, Hien Luong Doan, Amir Akhavanrezayat, Muhammad Sohail Halim, Diana V Do and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on biological therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 75 citations in OpenAlex.

  1. Response to anti-VEGF injections for diabetic macular edema among patients on chronic exogenous insulin therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Gunay UludagByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Muhammad HassanByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Wataru MatsumiyaByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Brandon Huy PhamByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Sophaktra CheaByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Ngoc Trong Tuong ThanByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Hien Luong DoanByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Amir AkhavanrezayatByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Muhammad Sohail HalimByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Diana V DoByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Quan Dong NguyenByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Smith-Kettlewell Eye Research Institute · USStanford University · USKobe University · JPOcular Surface Center · USUniversity of Miami · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

introductionDiabetic retinopathy (DR) is one of the most frequent microvascular complications of diabetes that can lead to blindness. Laser treatment has been the gold standard treatment for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) for many years. Recently, the role of vascular endothelial growth factor (VEGF) has been established in the pathogenesis of DR, and the use of intravitreal anti-VEGF therapy has gained popularity for the management of DR. AREAS COVERED: This review includes a brief overview of the efficacy and safety of currently available (bevacizumab, ranibizumab, and aflibercept) and potential future (brolucizumab, faricimab, and KSI-301) anti-VEGF agents in patients with DR based mainly on publicly available data from phase 1, 2 and 3 clinical trials. EXPERT OPINION: Clinical trials investigating the efficacy of intravitreal bevacizumab, ranibizumab, and aflibercept injections demonstrated favorable functional and anatomical outcomes in patients with DME. Moreover, the use of these anti-VEGF agents showed a significant improvement in the severity of DR. Recent clinical research for future anti-VEGF molecules aims to provide higher target-protein binding affinity and prolonged therapeutic effect. Brolucizumab, faricimab, and KSI-301 are three novel anti-VEGF agents that demonstrate promising data for the management of DME and potentially DR.

Indexed as

Diabetes MellitusDiabetic RetinopathyMacular EdemaAngiogenesis InhibitorsAntibodies, MonoclonalBevacizumabHumansIntravitreal InjectionsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, MonoclonalBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAfliberceptanti-vascular endothelial growth factorbevacizumabdiabetic macular edemadiabetic retinopathyranibizumabvascular endothelial growth factor

Identifiers

PMID35818801
PMCPMC10863998
OpenAlexW4285076984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.